International Clinical Trial: Development of Patient Derived Xenografts (PDXs) and Analysis of Tyrosine Kinase Receptor Expression in Patients With Squamous Cell Head and Neck Cancer (HNSCC) to Study Resistance Mechanisms Induced by Standard Therapy

Geneva, March 23 -- International Clinical Trials Registry received information related to the study (NCT07471009) titled 'Development of Patient Derived Xenografts (PDXs) and Analysis of Tyrosine Kinase Receptor Expression in Patients With Squamous Cell Head and Neck Cancer (HNSCC) to Study Resistance Mechanisms Induced by Standard Therapy' on March 10.

Study Type: Observational

Primary Sponsor: IRCCS Azienda Ospedaliero-Universitaria di Bologna

Condition: Squamous Cell Tumors of the Head and Neck (HNSCC)

Recruitment Status: Not recruiting

Date of First Enrollment: March 31, 2026

Target Sample Size: 120

Countries of Recruitment: Italy

To know more, visit https://clinicaltrials.gov/study/NCT07471009

Published by HT Digital Co...